Heerspink et al. assessed the levels of biomarkers in plasma samples from patients with T2D enrolled in a randomized clinical trial and found that treatment with canagliflozin decreased levels of tumor necrosis factor receptor-1 (TNFR1), interleukin-6 (IL-6), matrix metalloproteinase-7 (MMP7), and fibronectin-1 (FN1) levels compared with the glimepiride treatment, suggesting that canagliflozin can attenuate the molecular pathways related to inflammation and fibrosis [35]. This evidence concerns the gene FN1 and type 2 diabetes mellitus.